Vessy, Switzerland

Jérôme Pugin


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Oedema Treatment: The Contributions of Jérôme Pugin

Introduction

Jérôme Pugin, an inventive mind based in Vessy, Switzerland, has made significant contributions to the field of medicine. His pioneering research includes a patented invention that focuses on treating oedema, a condition characterized by an excess of watery fluid collecting in the cavities or tissues of the body.

Latest Patents

Jérôme holds a patent for "TNF-derived peptides for use in treating oedema." This innovative invention is based on the discovery that peptides derived from a specific domain of tumor necrosis factor-alpha (TNF-α) can efficiently treat this condition. More specifically, his patent pertains to the use of peptides derived from the human TNF-α region from Serto Gluto to treat pulmonary oedema. Notably, the circularized peptide with the amino acid sequence CGQRETPEGAEAKPWYC has demonstrated remarkable efficacy in inducing oedema resorption.

Career Highlights

Jérôme Pugin is currently associated with Innogenetics N.V., a company recognized for its advancements in biotechnology. His work there exemplifies the fusion of research and practical application, aiming to bridge the gap between laboratory findings and real-world medical treatments.

Collaborations

Throughout his career, Jérôme has collaborated with esteemed scientists, including Rudolf Lucas and Patrick De Baetselier. These collaborations have likely contributed to the robustness and credibility of his research, fostering an environment of shared knowledge and innovation in the field.

Conclusion

In conclusion, Jérôme Pugin is an exemplary inventor whose work on TNF-derived peptides represents a significant advancement in the treatment of oedema. His patent not only showcases his innovative spirit but also highlights the importance of collaborative research in advancing medical science. As he continues his work at Innogenetics N.V., the impact of his inventions will likely resonate in the medical community, paving the way for new treatment possibilities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…